Dr. Daniel S. Oh: Engineering the Future of Regenerative Dentistry

Dr. Daniel S. Oh stands at the forefront of biomaterials innovation—a scientist whose career bridges academia, technology, and clinical translation. With more than 25 years of research and leadership experience, he has become a defining voice in the field of bone regeneration and biomedical engineering.

Produced by Anthony and TereZa Lolli of Lolli Brands Entertainment, “Bye Ol’ Dentistry” is a groundbreaking international documentary exploring the oral-systemic connection and the future of biological dentistry. Dr. Oh’s participation in the film brings a crucial scientific dimension, revealing how regenerative technologies are reshaping the landscape of oral and maxillofacial care.

A Career in Translational Innovation

Daniel S. Oh, Ph.D., is the Chief Science Officer and Vice President of Osteogene Tech Corp (Osteogene), a commercial-stage bone regenerative company he co-founded in 2015. With more than 25 years of experience across academia and industry, Dr. Oh has dedicated his career to advancing biomaterials and biomedical engineering. Widely recognized as an innovator in translational medical research, his work bridges material science, biology, and clinical applications at the macro-, micro-, and nano-scales.

Dr. Oh’s participation in “Bye Ol’ Dentistry” goes beyond sharing his professional journey—it highlights groundbreaking progress in dentistry and bone regeneration. His life’s work is embodied in Osteogene’s flagship product, InRoad®, the first FDA-cleared engineered bioceramic bone graft designed to promote natural bone regeneration. InRoad® enhances blood absorption and circulation, emulates the biological microenvironment of bone without donor risks, and simplifies clinical procedures. This innovation has applications not only in dentistry but also in maxillofacial and orthopedic surgery.

Drawing on decades of research at Columbia University and the University of Texas at San Antonio, Dr. Oh helped bring this pioneering technology to market. Following FDA clearance and subsequent patient data collection, InRoad® adoption surged in 2025, with sales increasing more than 500% compared to 2024. That same year, Osteogene was awarded up to $1 million in matching funding from the New Jersey Economic Development Authority’s Angel Match Program to accelerate commercialization, strengthen distribution to dental practices, and support further research into new applications for its patented technology.

Origins and Mission of Osteogene

The origins of Osteogene trace back to a humanitarian relief trip to North Africa, where Dr. Oh and co-founder Dongwoo Sohn, Ph.D. (President, CEO, and board member), witnessed firsthand the limitations of available bone graft materials. Motivated by the urgent need for better clinical solutions, they established Osteogene Tech Corp with a mission to transform bone graft technology and improve patient outcomes.

Dr. Oh earned his Ph.D. in Materials Science and Engineering from Yeungnam University in 2003, focusing on implant coatings. He then pursued a postdoctoral fellowship at the University of Tennessee Health Science Center, followed by faculty roles at the University of Texas at San Antonio and later at Columbia University, where he contributed to both the Department of Orthopedic Surgery and the College of Dental Medicine. Beyond academia and industry, he serves as President of the non-profit On-Him Foundation.

His expertise lies in refining ceramic bone graft designs to ensure high compatibility with in vivo microenvironments, thereby supporting cell and growth factor infiltration and retention for enhanced bone regeneration. His research extends to developing advanced biomaterials for regenerative medicine, designing 3D culture systems with bioreactor technology to study stem cell development, and creating 3D cancer models for more accurate therapeutic screening.

Publications and Impact

To date, Dr. Oh has authored more than 65 research papers and book chapters and delivered over 165 scientific and medical presentations. His patented inventions—including bi-layered bone-like scaffolds and core-centered granules with micro-structured bodies—represent major advancements in treating bony defects. The bi-layered bone-like scaffold patent was commercialized as the InRoad® Engineered Ceramic Bone Graft, a spinoff innovation from his tenure at the University of Texas at San Antonio.

Today, Dr. Oh and the Osteogene team continue to push the boundaries of bone regeneration. The company is entering a new growth phase through strategic collaborations—partnering with global implant leaders to provide training and tools for dentists, and working with VA hospitals to advance care for U.S. veterans.

“Bye Ol’ Dentistry”: A Vision for Regenerative Health

“Bye Ol’ Dentistry” merges scientific insight and patient experience to reveal how oral health and systemic wellness are connected. Filmed across multiple continents, the documentary brings together innovators redefining the practice of dentistry through biologic, integrative, and regenerative science.

Dr. Oh’s inclusion underscores the bridge between medical engineering and modern dentistry. His work with Osteogene exemplifies how materials science can empower clinicians to restore structure and function naturally—without toxicity, inflammation, or dependency on outdated methods. Through the film, Dr. Oh joins a collective of global leaders demonstrating that the future of dentistry lies not in repair, but in regeneration.